COVID-19 Update: September 2022
![](/wp-content/uploads/2023/10/banners-website-25-1.png)
The ICC have updated their Covid-19 guidance for people with FOP after a meeting of the members.
The following guidance also explains about the Covid-19 vaccine. The current advice is that “the ICC is unable to recommend for or against the Covid vaccine for patients with FOP. The decision to take a vaccine is a personal one and based on the balance of risks and benefits, and this should be discussed with your medical team.”
These guidelines are written with an international viewpoint. It is advised that the current NHS guidance for the UK is also taken into consideration, especially in light of the new strain of Covid-19 which is believed to spread more quickly.
For patients, families and carers, please SCROLL DOWN THIS PAGE TO READ THE ADVICE from the International Clinical Council for FOP.
Read the updated ICC Guidelines here.
For up to date NHS advice on Covid-19, please visit: www.nhs.uk/conditions/coronavirus-covid-19
![](/wp-content/uploads/2021/03/vaccine-400.jpg)
The Coronavirus (COVID-19) pandemic continues to pose a significant risk to the population worldwide with new variants of SARS-CoV-2 virus are emerging.
There have also been reports on non-genetic heterotopic ossification developing in NON-FOP patients with COVID-19 infections.
The ICC recommends that people living with FOP to continue to follow strict precautionary measures to prevent infection from SARS-CoV-2, the virus that causes the COVID-19 illness.
To download the latest ICC Covid Guidelines click here.
May 2022
The recommendations are changing rapidly, are country specific and based on COVID-19 vaccine availability:
The ICC does not provide recommendations on whether a patient with FOP should or should not receive a COVID vaccine.
The decision to take a vaccine is a personal one and based on the balance of risks and benefits, and this should be discussed with your medical team. ICC continues to recommend that COVID-19 vaccines be administered that same route that it was approved (i.e. intramuscular).
Additional information about COVID-19 and COVID vaccination in patients with FOP is now published. https://ojrd.biomedcentral.com/articles/10.1186/s13023-022-02246-4
* Amongst 15 FOP patients who received intramuscular COVID-19 vaccination. Most common symptoms were pain/soreness, tiredness and swelling. 1 out of 15 developed a flare up and none were hospitalized.
* Amongst 10 FOP patients with COVID-19 infection. Most common symptoms were fatigue, loss of taste or smell and cough. 2 out 10 FOP patient developed flare ups and 1 patient was hospitalized.
Vaccines are now generally available for children age 5 or over. ICC does not provide recommendations on whether a patient with FOP should or should not receive a COVID vaccine
ICC does not provide recommendations for or against the booster vaccination, but boosters should be considered if you completed vaccinations previously and are in a high risk area. Please consult with your medical team prior to receiving the booster to discuss if a booster is appropriate and safe.
Patients with FOP are at high risk of complications with COVID-19 infection and should discuss with their medical team if use of monoclonal antibodies or anti-retroviral medications would be beneficial, in the event of a SARS-CoV2 infection.
* Monoclonal antibodies are given intravenously and are approved for adults and pediatric patients (≥12 years of age weighing ≥40 kg). Those innervations should be started as early as possible and before 10 days of symptoms onset.
* Anti-retrovirals are pills that have been approved. These should generally be administered within 5 days of symptoms onset.
* Availability and recommendations of the use of these treatments are rapidly changing and country specific. Some of these therapies may not work against strains prevalent in a particular region. Please consult with your local medical team for recommendations
* Discuss with your doctors to make sure there are no medication interactions
Thank you to all of our prior participants who have contributed clinical data about FOP and COVID/SARS-CoV2 infection. The studies at UCSF have now concluded and are published here:
Social and clinical impact of COVID-19 on patients with fibrodysplasia ossificans progressiva | Orphanet Journal of Rare Diseases | Full Text (biomedcentral.com)
https://ojrd.biomedcentral.com/articles/10.1186/s13023-022-02246-4
Masking continues to be an important component of controlling the spread of SARS-CoV-2. The ICC strongly recommends the use of tight fitting N95, KN95, or KF94 masks whenever possible to protect the wearer from infection by SARS-CoV-2. If these masks are not available or uncomfortable, then wearing a 3 layer surgical mask would be the next best choice.
The ICC is aware of a recent publication suggesting that the use of subcutaneous needles could still induce adequate vaccine response. However, this study likely delivered the vaccine via a shallow intramuscular route. Furthermore, there are multiple reports in the literature of severe reactions to subcutaneous injection of the COVID vaccine. Efficacy of subcutaneous delivery of a COVID vaccine remains unproven. Therefore, the ICC continues to recommend following the manufacturers’ directions for vaccination and NOT taking intramuscular COVID vaccines by the subcutaneous route.
Download the ICC Covid guidelines here.
![](/wp-content/uploads/2021/03/hand-disinfection-400.jpg)
![](/wp-content/uploads/2021/03/hand-wash-400-v2.jpg)
![](/wp-content/uploads/2021/03/sanitizing-400.jpg)
![](/wp-content/uploads/2021/03/girl-5760039_1920.jpg)
![](/wp-content/uploads/2021/03/mobile-phone-400.jpg)
![](/wp-content/uploads/2021/03/vial-400.jpg)
![](/wp-content/uploads/2021/03/rainbow-400.jpg)